First Received: February 22, 2011 Last Updated: February 23, 2011
Sponsor: Santhera Pharmaceuticals
Information provided by: Santhera Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01303406
Locations: United Kingdom, The National Hospital, University College London
Principal Investigator: Paola Giunti, M.D, Institute of Neurology, The National Hospital, University College London
Thursday, February 24, 2011
The potential application of iron chelators for the treatment of neurodegenerative diseases.
Metallomics. 2011 Feb 22. [Epub ahead of print]
Hider RC, Roy S, Ma YM, Le Kong X, Preston J.
King's College London, Institute of Pharmaceutical Science, London
Keywords: neurodegenerative disease, Alzheimer's disease, Parkinson's disease, Friedreich's ataxia, Hallervorden Spatz syndrome and macular degeneration, redox active metals, copper, iron, selective chelation.
Hider RC, Roy S, Ma YM, Le Kong X, Preston J.
King's College London, Institute of Pharmaceutical Science, London
Keywords: neurodegenerative disease, Alzheimer's disease, Parkinson's disease, Friedreich's ataxia, Hallervorden Spatz syndrome and macular degeneration, redox active metals, copper, iron, selective chelation.
Subscribe to:
Posts (Atom)
